A Phase Ib Study of Cryoablation and Pressure-enabled Hepatic Arterial Infusion of Class C Toll-like Receptor 9 Agonist SD-101 in Combination With Durvalumab and Tremelimumab in Patients With Advanced Hepatocellular Carcinoma
Latest Information Update: 26 May 2026
At a glance
- Drugs Nelitolimod (Primary) ; Durvalumab; Tremelimumab
- Indications Carcinoma; Liver cancer; Seizures
- Focus Adverse reactions
Most Recent Events
- 11 Feb 2025 Status changed from not yet recruiting to recruiting.
- 02 Dec 2024 New trial record